MedTrace Logo

Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients

NCT00132210 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2010-10-21

No results posted yet for this study

Summary

The purpose of this study is to determine whether pegylated interferon therapy is effective to treat acute hepatitis C infection in HIV-coinfected individuals.

Conditions

  • Hepatitis C
  • HIV Infections

Interventions

DRUG

pegylated interferon

Pegylated interferon alfa-2a or -2b in standard dosage Ribavirin in case of genotype 1 or 4 at 1000 or 1200 mg/d according to body weight ist recommended.

Sponsors & Collaborators

  • University Hospital, Bonn

    lead OTHER

Principal Investigators

  • Jürgen K Rockstroh, MD, PhD · Medical Department I, University Hospital, Bonn University, Germany

  • Martin Vogel, MD · Medical Department I, University Hospital, Bonn University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00132210 on ClinicalTrials.gov